MORE THAN HEALTH ON LINE IN PATENT DEBATE

Investors will attest that IP is at the core of any life sciences company valuation, and as such, the life of the patent and the data exclusivity once a company gets their product to market is of paramount importance when assessing an investment's potential.

Saved in:
Bibliographic Details
Published inHerald-Sun news-pictorial
Main Author Cross, Glenn
Format Newspaper Article
LanguageEnglish
Published Melbourne, Vic Nationwide News Pty Ltd 23.09.2016
Subjects
Intellectual property
Life sciences
Medical research
Pharmaceutical industry
Product development
Regulatory approval
United States > US
Australia
Online AccessGet full text

Cover

More Information
Summary:Investors will attest that IP is at the core of any life sciences company valuation, and as such, the life of the patent and the data exclusivity once a company gets their product to market is of paramount importance when assessing an investment's potential.
ISSN:1038-3433